← Leaderboards
Vassiliki Saloura
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Division Of Basic Sciences - Nci
Same institution · by research overlap
Others in their field
Top investigators on “Head And Neck Squamous Cell Carcinoma”
- Jennifer R Grandis · University Of Pittsburgh At Pittsburgh$17,047,548
- Cun-Yu Wang · University Of California Los Angeles$14,843,475
- Lorraine J Gudas · Sloan-Kettering Institute For Cancer Res$11,559,006
- Qingyi Wei · University Of Texas Md Anderson Can Ctr$11,102,171
- Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh$10,353,289
- Xiao-Jing Wang · University Of California At Davis$9,895,933
Research focus
Head And Neck Squamous Cell CarcinomaRecurrenceHead And Neck Cancer PatientResponseTranscriptome SequencingImmuneCd8-Positive T-LymphocytesProgression-Free SurvivalsTumorHead And Neck CancerGenesClinical TrialsSafetyDrug KineticsCellsCancer CellGenome-WideRadiation TherapyOncogenicToxic EffectHpv-Negative Head And Neck CancerExome SequencingHistonesBlood Specimen
Grant awards (21)
The Role of Protein Methylation in Squamous Cell Carcinoma of the Head and Neck$1,435,614
ZIA · FY2025 · CA · contact PI
Neoadjuvant Photoimmunotherapy in Head and Neck Cancer$29,600
ZIA · FY2025 · CA · contact PI
IMRRT for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma$14,799
ZIA · FY2025 · CA · contact PI
The Role of Protein Methylation in Squamous Cell Carcinoma of the Head and Neck$1,300,908
ZIA · FY2024 · CA · contact PI
Valemetostat in combination with pembrolizumab in head and neck cancer$13,412
ZIA · FY2024 · CA · contact PI
Neoadjuvant Photoimmunotherapy in Head and Neck Cancer$13,412
ZIA · FY2024 · CA · contact PI
IMRRT for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma$13,412
ZIA · FY2024 · CA · contact PI
The Role of Protein Methylation in Squamous Cell Carcinoma of the Head and Neck$1,355,075
ZIA · FY2023 · CA · contact PI
Neoadjuvant Photoimmunotherapy in Head and Neck Cancer$13,970
ZIA · FY2023 · CA · contact PI
Valemetostat in combination with pembrolizumab in head and neck cancer$13,970
ZIA · FY2023 · CA · contact PI
IMRRT for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma$13,970
ZIA · FY2023 · CA · contact PI
The Role of Protein Methylation in Squamous Cell Carcinoma of the Head and Neck$953,405
ZIA · FY2022 · CA · contact PI
IMRRT for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma$9,729
ZIA · FY2022 · CA · contact PI
Neoadjuvant Photoimmunotherapy in Head and Neck Cancer$9,729
ZIA · FY2022 · CA · contact PI
The Role of Protein Methylation in Squamous Cell Carcinoma of the Head and Neck$607,723
ZIA · FY2021 · CA · contact PI
IMRRT for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma$6,139
ZIA · FY2021 · CA · contact PI
The Role of Protein Methylation in Squamous Cell Carcinoma of the Head and Neck$684,120
ZIA · FY2020 · CA · contact PI
IMRRT for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma$6,911
ZIA · FY2020 · CA · contact PI
The Role of Protein Methylation in Squamous Cell Carcinoma of the Head and Neck$577,341
ZIA · FY2019 · CA · contact PI
IMRRT for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma$5,831
ZIA · FY2019 · CA · contact PI
The Role of WHSC1L1 in Squamous Cell Carcinoma of the Head and Neck$637,808
ZIA · FY2018 · CA · contact PI